The Institute of Global Health Innovation at Imperial College London has published a report called “NHS data: Maximising its impact on the health and wealth of the United Kingdom” (the “Report”).[1] The Report begins from the premise that the knowledge gleaned from the combination of patient health data and “big data” technologies has incredible potential for “transformative …impact” on patient health, scientific advancement and the UK’s economy. However, the Report argues that the current efforts of scientists, medical professionals and the UK government to develop the UK’s capacities are not sufficiently coordinated to maximise that potential. To address this, the Report presents a single, high-level, strategic framework for the collection, governance and use of patient health data in the NHS.
Continue Reading New Report Recommends Putting Public Engagement at the Heart of NHS Health Data Strategy
Seán Finan
Seán Finan is an associate in the Life Sciences team. His practice covers environmental, food and beverage and pharmaceutical regulation.
Seán has specific experience in a number of key areas for EU and UK clients in the technology, food and beverage, pharmaceutical, cosmetic and consumer goods industries, including:
- Environmental and ESG compliance issues, including CSRD, CSDDD and green taxonomy issues; green public procurement issues; extended producer responsibility obligations, etc.;
- Advertising claims, particularly environmental claims and greenwashing;
- General food regulation; novel food regulation; genetically modified and "precision bred" products; and
- Chemicals legislation (REACH, CLP, biocides, etc.).
Seán has represented clients in judicial review actions involving novel foods against multiple national regulators.
Seán is qualified in both England & Wales, and the Republic of Ireland.
Seán is a co lead of the firm's Disability and Mental Health affinity group.
Contact:Read more about Seán FinanEmail